Jump to main content.

Acrylonitrile Quickview (CASRN 107-13-1)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Acrylonitrile

File First On-Line: 09/30/1987; Last Significant Revision: 11/01/1991

Category (section)
Last Revised
Oral RfD Assessment No
Inhalation RfC Assessment Yes 11/01/1991
Carcinogenicity Assessment Yes 09/30/1987
Under Re-Assessment
  • 107-13-1
  • Acritet
  • Acrylnitril
  • Acrylon
  • Acrylonitrile
  • Acrylonitrile monomer
  • Akrylonitryl
  • Carbacryl
  • Cianuro di vinile
  • Cyanoethylene
  • Cyanure de vinyle
  • more...
Acrylonitrile Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Not Assessed under the IRIS Program.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells LOAEL (HEC): 1.9 mg/m3 1000 2x10-3 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans)
  • Weight-of-Evidence Narrative:
    • The observation of a statistically significant increase in incidence of lung cancer in exposed workers and observation of tumors, generally astrocytomas in the brain, in studies in two rat strains exposed by various routes (drinking water, gavage, and inhalation) forms the basis for this classification.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)
Extrapolation Method
5.4 x10-1 per mg/kg-day Linearized multistage procedure, extra risk
Drinking Water Unit Risks
1.5x10-5 per µg/L
Risk Level
E-4 (1 in 10,000) 6 µg/L
E-5 (1 in 100,000) 6x10-1 µg/L
E-6 (1 in 1,000,000) 6x10-2 µg/L
  • Dose-Response Data (Carcinogenicity, Oral Exposure)
    • Tumor Type: Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas
    • Test Species: Rats (Spartan Sprague-Dawley, males Fischer 344, males Sprague-Dawley, males)
    • Route: Oral, Drinking water
    • Reference: Biodynamics, 1980a,b Quast et al., 1980a

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)
Extrapolation Method
6.8 x10-5 per µg/m3 Average relative risk

Inhalation Concentrations at Specified Risk Levels

Risk Level
E-4 (1 in 10,000) 1 µg/m3
E-5 (1 in 100,000) 1x10-1 µg/m3
E-6 (1 in 1,000,000) 1x10-2 µg/m3

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.